



The H1 histamine receptor blocker, chlorpheniramine, completely prevents the increase in REM sleep induced by immobilization stress in rats

J.A. Rojas-Zamorano, E. Esqueda-Leon, A. Jimenez-Anguiano, L. Cintra-McGlone, M.A. Mendoza Melendez, J. Velazquez Moctezuma*

Department of Biology of Reproduction, Universidad Autonoma Metropolitana-Iztapalapa, CP 09340, Mexico City, Mexico

ARTICLE INFO

Article history:

Received 10 April 2008

Received in revised form 8 July 2008

Accepted 16 July 2008

Available online 22 July 2008

Keywords:

Chlorpheniramine

Stress

REM sleep

Antihistaminics

ABSTRACT

Chlorpheniramine is a selective antagonist of the H1 histaminergic receptor subtype and its effects in humans include somnolence. Chlorpheniramine affects sleep in rats, mainly by decreasing REM sleep. On the other hand, stress by immobilization induces an important increase in the percentage of REM sleep. In this study we analyzed the effects of blocking histaminergic receptors on REM sleep induced by immobilization stress. Adult male Wistar rats were chronically implanted for sleep recording. Immobilization stress was induced by placing the rat in a small cylinder for 2 h. Experimental conditions were: A. Control; B. Stress; C. Stress plus vehicle and D. Stress plus chlorpheniramine. Independent experiments were done both in the dark, as well as the light period. Results showed that the increase in REM sleep observed after immobilization stress was completely abolished by chlorpheniramine, both in the dark and in the light phase. Furthermore, the decrease in REM sleep was significant even when compared to the non-stressed control rats. REM sleep latency was also significantly longer during both light phases. The present results suggest that REM sleep is quite sensitive to histaminergic blockage. It is possible that chlorpheniramine is also blocking the cholinergic mechanisms generating REM sleep.

© 2008 Elsevier Inc. All rights reserved.

1. Introduction

The histaminergic neurons are mainly located in the tuberomammillary nucleus, from where they widely project to several areas of the central nervous system (Lin, 2000). Histamine receptors have been classified into three subtypes (H1, H2 and H3) according to their pharmacological characteristics. Both the H1 and the H2 histaminergic receptor subtypes are located postsynaptically, while the H3 subtype is located in both the pre- and postsynaptic membrane (for review see: Hill et al., 1997). Chlorpheniramine (CPA) is a well known antagonist of the H1 histamine receptor subtype (Gutkowski et al., 1985). CPA was among the first available antihistamines and has been widely used because of its effectiveness as an antiallergenic agent (Gutkowski et al., 1985). CPA readily crosses the blood brain barrier and one of its collateral effects is the induction of sedation (Bassano and Caille, 1979; Boyle et al., 2006). In fact, this sedative effect forced the industry to develop a second generation of non-sedative antihistamines (Slater, 1999; Mann et al., 2000). However, the effects of CPA on sleep have been controversial and the sedative effect is not

always observed (Karamanakos et al., 2004; Karamanakos, 2007). Nevertheless, a clear inhibition of the REM sleep stage has been reported systematically after administration of CPA (Wauquier and Niemegeers, 1981; Saitou et al., 1999). Moreover, this effect has been observed in several species, including humans (Nicholson et al., 2004).

On the other hand, growing evidence indicates a close relationship between the stress response and the sleep pattern (Bodosi et al., 2000; Bonnet et al., 2000; Zhang et al., 1988). One of the most conspicuous features of this relationship is the induction of REM sleep after 2 h of stress by immobilization (Rampin et al., 1991). This notable increment in REM sleep implies the participation of a number of neurotransmitter systems. Studies using neurotoxin DSP-4 have indicated a mediation of noradrenergic neurons (Gonzalez et al., 1995). Voltametric analysis of the serotonergic neurons in the raphe nucleus has shown that there is an activation after immobilization stress (Cespuoglio et al., 1995; Houdouin et al. 1991). Furthermore, studies using naltrexone have indicated that the opioidergic system is also involved in the increase in REM sleep after immobilization stress (Vazquez-Palacios et al., 2004).

Histaminergic neurons located in the tuberomammillary nucleus have been involved in the stress response (Endou et al., 2001; Watanabe and Yanai, 2001). Thus, it is possible that the histaminergic system also participates in the induction of REM sleep by stress. In the present study, CPA, an H1 histaminic receptor blocker that commonly

* Corresponding author. Tel./fax: +52 558044704.

E-mail address: jvm@xanum.uam.mx (J. Velazquez Moctezuma).




Fig. 1. Percentage of sleep stages in 8 h of polygraphic recordings after 2 h of stress by immobilization. Panel A: recording during the light period. Panel B: recording during the dark period. Control: no manipulation; stress: 2 h of immobilization; VH-stress: 2-hour immobilization stress plus 0.2 ml vehicle IP; CPA-stress: 2-hour immobilization stress plus 20 mg/kg bw chlorpheniramine IP. * $p < 0.05$ compared to control.

suppresses naturally occurring REM sleep, was administered to prevent the increase in REM induced by immobilization in rats.

2. Methods

Adult male Wistar rats (350–400 g bw), bred in our own vivarium were used. Animals were housed in standard vivarium conditions and under 12/12 normal light/dark cycle (lights on 9:00 AM) with food and water available *ad libitum*. All procedures were in accordance to the *Guide for the Care and Use of Laboratory Animals* of the NIH. Under deep general anesthesia induced with a cocktail (ketamine: 3.75 mg/100 g; xylazine: 0.19 mg/100 g and acepromazine: 0.038 mg/100 g ip), rats were chronically implanted with a standard set of electrodes for sleep recording. After a two-week recovery period, the rats were habituated to the experimental cages for 24 h.

EEG and EMG were recorded for 8 h (9:00–17:00 h). Recordings were scored in a blind fashion and following previously published criteria (Takeuchi, 1970). Immobilization stress was achieved by placing the animal inside a plexiglass cylinder during the 2 h prior to the lights turned on. Recordings were obtained after the following conditions:

- Control: ($N=14$)
- Stress: After 2 h of stress by immobilization, without any injection. ($N=10$)
- Stress plus the administration of vehicle. ($N=8$)
- Stress plus CPA (chlorpheniramine maleate (Sigma) 20 mg/kg bw) dissolved in an ethanol/water solution. Doses were injected IP at the end of the stress period and in a 0.2 volume ml. ($N=9$)

The same procedure was repeated with the other rats during the dark phase of the cycle. Therefore, the stress was applied during the

last 2 h of the light–dark cycle and recordings started when the lights went off. The number of subjects in the dark period groups was:

- Control ($N=13$)
- Stress ($N=10$)
- Stress plus vehicle ($N=10$)
- Stress plus CPA ($N=10$)

2.1. Statistical analysis

Data were analyzed using the Kruskal–Wallis ANOVA followed, when significant, by Kruskal–Wallis post-hoc test between pairs to find the source of significance.

3. Results

Fig. 1 shows the percentages of the different sleep stages. During the light phase of the cycle (Panel A), both wakefulness and SWS did not show any significant modifications in any of the conditions tested. REM sleep showed a trend to increase in the stress (B) and stress plus vehicle group (C). The stressed group treated with CPA (D) showed a significant decrease compared to the control group. During the dark phase of the light–dark cycle (Panel B) the stressed group treated with vehicle and with CPA showed a trend to decrease that did not reach statistical significance. SWS showed an increase that reached statistical significance in the stressed groups treated with CPA (H). Concerning REM sleep, a significant increase was observed in the stressed group (F) and in the stressed group treated with vehicle (G). The stressed group treated with CPA, however, showed a significant decrease even when compared with control.




Fig. 2. Latencies to REM sleep after a 2-hour immobilization stress. Panel A: recording during the light period. Panel B: recording during the dark period. Control: no manipulation; stress: 2-hour immobilization stress; VH-stress: 2-hour immobilization stress plus 0.2 ml vehicle IP; CPA-stress: 2-hour immobilization stress plus 20 mg/kg bw chlorpheniramine IP. * $p < 0.05$ compared to control.




Fig. 3. Frequency of REM sleep bouts in 8 h of polygraphic recordings after a 2-hour immobilization stress. Panel A: recording during the light period. Panel B: recording during the dark period. Control: no manipulation; stress: 2-hour immobilization stress; VH-stress: 2-hour immobilization stress plus 0.2 ml vehicle IP; CPA-stress: 2-hour immobilization stress plus 20 mg/kg bw chlorpheniramine IP. * $p < 0.05$ compared to control. + $p < 0.05$ compared to all the groups.

REM sleep latencies are displayed in Fig. 2. A significant increase in REM latency is observed in the stressed group treated with CPA when compared to the control group. This effect was observed in both phases of the light–dark cycle.

Fig. 3 shows the analysis of REM sleep bouts frequency. During the light phase of the light–dark cycle (upper panel) there was an increase in REM frequency due to stress, however, it did not reach statistical significance. When CPA was administered to stressed rats, REM sleep frequency decreased to even lower values than those of the control group. During the dark phase of the light–dark cycle (lower panel), stressed groups showed a significant increase in REM sleep frequency compared to controls. When CPA was administered to stressed rats, the frequency in REM sleep returns to control values.

4. Discussion

Ever since the pioneering studies of Rampin et al. (1991), the notable increase in REM sleep after stress in rats has been repeatedly corroborated (Palma et al., 2000). Some determinants of the effect have been characterized as the nature of the stress (Velazquez-Moctezuma et al., 1993), the duration of the stress (Marinesco et al., 1999; Bonnet et al., 2000), the influence of the circadian cycle (Koehl et al., 2002), among others. Although the rats spent the 2 h of stress mostly awake, the increase in REM sleep after immobilization is not due to sleep deprivation. Rampin et al. (1991) have compared immobilization with sleep deprivation for 2 h and the increase in REM sleep is absent in the sleep deprived rats. Concerning the participation of different neurotransmitter systems, some reports indicate the participation of the noradrenergic system (Gonzalez et al., 1995), of the serotonergic system (Sinha, 2006; Haleem et al., 2007) and even of the opioidergic system (Vázquez-Palacios et al., 2004).

On the other hand, the participation of the histaminergic system in the sleep–wake cycle has been a matter of controversy for years.

Vanni-Mercier et al. (2003) have recorded histaminergic neurons located in the tuberomammillary system that display maximum activity during wakefulness; it decreases during SWS and are almost silent during REM sleep. Histamine H1 receptor antagonists including mepyramine, diphenhydramine, and chlorpheniramine reduce waking and REMS and increase SWS in rats and/or dogs (Monti et al., 1986; Wauquier et al., 1981). However, the only systematic result obtained after the administration of antihistamines that block the H1 receptor is a clear reduction of REM sleep (Wauquier et al., 1981; Saitou et al., 1999; Nicholson et al., 2004; Marzanatti et al., 1989). Furthermore, experiments in knockout mice lacking the H1 histaminergic receptor show no alteration of sleep features (Huang et al., 2006). Thus, although the histaminergic system is involved in REM sleep regulation, its mechanism of participation is not clear.

Moreover, the cholinergic regulation of REM sleep is well known. Stimulation of muscarinic receptors mainly at pontine level readily generates a remarkable increase in REM sleep (Velazquez-Moctezuma et al., 1990). It has been suggested that the M2 muscarinic receptors subtypes are responsible for this increase in REM sleep by pontine stimulation (Velazquez-Moctezuma et al., 1989, 1991) although systemic administration of M1 muscarinic blockers in rats suggests that the M1 muscarinic receptor subtype is also involved in REM sleep regulation (Zoltowski et al., 1993). In addition, it has been reported that H1 histamine receptor blockers, including chlorpheniramine, have a clear antimuscarinic action (Orzechowski et al., 2005). Thus, it is possible that blockade of muscarinic receptors by chlorpheniramine is the cause of the decrease observed in the percentage of REM sleep in stressed animals. Nevertheless, considering that histaminergic neurons fire during wakefulness and are silent during REM sleep, the inhibitory influence of histaminergic blockers on REM sleep could include the participation of more than one neurotransmitter system. The exact mechanism remains to be elucidated.

Acknowledgments

The authors want to express their gratitude to Edith Monroy for her expert review of the language of the manuscript. The study was partly supported by CONACYT Grant # 193082 (JARZ). This study is part of the doctoral degree in Experimental Biology of JARZ at the Universidad Autónoma Metropolitana.

References

- Bassano JL, Caille EJ. Effects of two antihistaminic compounds (mequitazine, dexchlorpheniramine) on sleep. Sleep distortion by antihistaminics. *Waking Sleep* 1979;3:57–61.
- Bodosi B, Obál Jr F, Gardi J, Komlódi J, Fang J, Krueger JM. An ether stressor increases REM sleep in rats: possible role of prolactin. *Am J Physiol, Regul Integr Comp Physiol* 2000;279:R1590–8.
- Bonnet C, Marinesco S, Debilly G, Kovalzon V, Cespuglio R. Influence of a 1-h immobilization stress on sleep and CLIP brain contents in adrenalectomized rats. *Brain Res* 2000;853:323–9.
- Boyle J, Eriksson M, Stanley N, Fujita T, Kumagi Y. Allergy medication in Japanese volunteers: treatment effect of single doses on nocturnal sleep architecture and next day residual effects. *Curr Med Res Opin* 2006;22:1343–51.
- Cespuglio R, Marinesco S, Baubet V, Bonnet C, el Kafi B. Evidence for a sleep-promoting influence of stress. *Adv Neuroimmunol* 1995;5:145–54.
- Endou M, Yanai K, Sakurai E, Fukudo S, Hongo M, Watanabe T. Food-deprived activity stress decreased the activity of the histaminergic neuron system in rats. *Brain Res* 2001;891:32–41.
- Gonzalez MM, Debilly G, Valatx JL, Jouvét M. Sleep increase after immobilization stress: role of the noradrenergic locus coeruleus system in the rat. *Neurosci Lett* 1995;202:5–8.
- Gutkowski A, Del Carpio J, Gelinás B, Schulz J, Turenne Y. Comparative study of the efficacy, tolerance and side-effects of dexchlorpheniramine maleate 6 mg b.i.d. with terfenadine 60 mg b.i.d. *J Int Med Res* 1985;13:284–8.
- Haleem DJ, Samad N, Perveen T, Haider S, Haleem MA. Role of serotonin-1A receptors in restraint-induced behavioral deficits and adaptation to repeated restraint stress in rats. *Int J Neurosci* 2007;117:243–57.
- Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. *Pharmacol Rev* 1997;49(3):253–78.
- Houdouin F, Cespuglio R, Gharib A, Sarda N, Jouvét M. Detection of the release of 5-hydroxyindole compounds in the hypothalamus and the n. raphe dorsalis throughout

- the sleep–waking cycle and during stressful situations in the rat: a polygraphic and voltammetric approach. *Exp Brain Res* 1991;85:153–62.
- Huang ZL, Mochizuki T, Qu WM, Hong ZY, Watanabe T, Urade Y, et al. Altered sleep–wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice. *Proc Natl Acad Sci U S A* 2006;103:4687–92.
- Karamanakos PN. Can chlorpheniramine cause serotonin syndrome? *Singap Med J* 2007;48:482.
- Karamanakos PN, Pappas P, Marselos M. Involvement of the brain serotonergic system in the locomotor stimulant effects of chlorpheniramine in Wistar rats: implication of postsynaptic 5-HT1A receptors. *Behav Brain Res* 2004;148:199–208.
- Lin J. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. *Sleep Med Rev* 2000;4:471–503.
- Koehl M, Bouyer JJ, Darnaudéry M, Le Moal M, Mayo W. The effect of restraint stress on paradoxical sleep is influenced by the circadian cycle. *Brain Res* 2002;937:45–50.
- Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with non sedating antihistamines four prescription event monitoring studies in general practice. *BMJ* 2000;320:1184–6.
- Marinesco S, Bonnet C, Cespuglio R. Influence of stress duration on the sleep rebound induced by immobilization in the rat: a possible role for corticosterone. *Neuroscience* 1999;92:921–33.
- Marzanatti M, Monopoli A, Trampus M, Ongini E. Effects of non-sedating histamine H1-antagonists on EEG activity and behavior in the cat. *Pharmacol Biochem Behav* 1989;32:861–6.
- Monti JM, Pellejero T, Jantos H. Effects of H1- and H2-histamine receptor agonists and antagonists on sleep and wakefulness in the rat. *J Neural Transm* 1986;66(1):1–11.
- Nicholson AN, Pascoe PA, Turner C, Ganellin CR, Greengrass PM, Casy AF, et al. Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. *Pediatrics* 2004;113:e116–21.
- Orzechowski RF, Currie DS, Valancius CA. Comparative anticholinergic activities of 10 antihistamine H1 receptor antagonists in two functional models. *Eur J Pharmacol* 2005;506:257–64.
- Palma BD, Suchecki D, Tufik S. Differential effects of acute cold and footshock on the sleep of rats. *Brain Res* 2000;861:97–104.
- Rampin C, Cespuglio R, Chastrette N, Jouvet M. Immobilisation stress induces a paradoxical sleep rebound in rat. *Neurosci Lett* 1991;126:113–8.
- Saitou K, Kaneko Y, Sugimoto Y, Chen Z, Kamei C. Slow wave sleep-inducing effects of first generation H1-antagonists. *Biol Pharm Bull* 1999;22:1079–82.
- Sinha RK. P-CPA pretreatment reverses the changes in sleep and behavior following acute immobilization stress rats. *J Physiol Sci* 2006;56:123–9.
- Slater JW. Second-generation antihistamines: a comparative review. *Drugs* 1999;57:1033–4.
- Takeuchi E. Polygraphical study on the wakefulness–sleep cycle of the rat. *Shinrigaku Kenkyu* 1970;41:248–56.
- Vanni-Mercier G, Gigout S, Debilly G, Lin JS. Waking selective neurons in the posterior hypothalamus and their response to histamine H3-receptor ligands: an electrophysiological study in freely moving cats. *Behav Brain Res* 2003;144:227–41.
- Vázquez-Palacios G, Retana-Márquez S, Bonilla-Jaime H, Velázquez-Moctezuma J. Stress-induced REM sleep increase is antagonized by naltrexone in rats. *Psychopharmacol* 2004;171:186–90.
- Velázquez-Moctezuma J, Gillin JC, Shiromani JP. Effect of specific M1,M2 muscarinic receptor antagonists on REM sleep generation. *Brain Res* 1989;503:128–31.
- Velázquez-Moctezuma J, Shiromani JP, Gillin JC. Acetylcholine and acetylcholine receptor subtypes in REM sleep generation. In: Aquilonius SM, Gillberg PG, editors. *Cholinergic Regulation*. Progress in Brain Research Amsterdam: Elsevier; 1990. p. 407–13.
- Velázquez-Moctezuma J, Shalauta M, Gillin JC, Shiromani PJ. Cholinergic antagonists and REM sleep generation. *Brain Res* 1991;543(1):175–9.
- Velázquez-Moctezuma J, Dominguez Salazar E, Cruz Rueda ML. The effect of prenatal stress on adult sexual behavior in rats depends on the nature of the stressor. *Physiol Behav* 1993;53:443–8.
- Watanabe T, Yanai K. Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography. *Tohoku J Exp Med* 2001;195:197–217.
- Wauquier A, Niemegeers CJ. Effects of chlorpheniramine, pyrilamine and astemizole on intracranial self-stimulation in rats. *Eur J Pharmacol* 1981;72:245–8.
- Wauquier A, Van den Broeck WA, Awouters F, Janssen PA. A comparison between astemizole and other antihistamines on sleep–wakefulness cycles in dogs. *Neuropharmacology* 1981;20(9):853–9.
- Zhang JX, Valatx JL, Jouvet M. Hypophysectomy in monosodium glutamate-pretreated rats suppresses paradoxical sleep rebound. *Neurosci Lett* 1988;86:94–8.
- Zoltowski RK, Velázquez-Moctezuma J, Shiromani PJ, Gillin JC. The relative effects of selective M1 muscarinic antagonists on rapid eye movement sleep. *Brain Res* 1993;608:186–90.